ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

IDIX (MM)

24.50
0.00 (0.00%)
Pre Market
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
(MM) NASDAQ:IDIX NASDAQ Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 24.50 0.00 01:00:00

Idenix Pharmaceuticals to Present at the Cowen & Company 27th Annual Healthcare Conference

06/03/2007 9:05pm

PR Newswire (US)


(MM) (NASDAQ:IDIX)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more (MM) Charts.
CAMBRIDGE, Mass., March 6 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) announced today that Idenix management will attend the upcoming Cowen & Company 27th Annual Healthcare Conference on Tuesday, March 13, 2007 at The Boston Marriott Copley Place. Idenix will present a corporate overview, including an update of the company's commercialization activities and discovery and development programs at 10:15 a.m. EDT. The live and archived webcast of the company presentation can be accessed under "Calendar of Events" in the Idenix Investor Center at http://www.idenix.com/. Please log in approximately 5-10 minutes before the event to ensure a timely connection. The archived replay will be available on the Idenix website for two weeks following the conference. The company presentation will be available for download in PDF format in the "Investor Presentations" section of the Investor Center immediately following the presentation. About Idenix Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by hepatitis B virus, hepatitis C virus and human immunodeficiency virus (HIV). For further information about Idenix, please refer to http://www.idenix.com/. Idenix Pharmaceuticals' Contacts: Media: Teri Dahlman (617) 995-9905 Investors: Amy Sullivan (617) 995-9838 DATASOURCE: Idenix Pharmaceuticals, Inc. Contact: media, Teri Dahlman of Idenix Pharmaceuticals, +1-617-995-9905, or investors, Amy Sullivan +1-617-995-9838 Web site: http://www.idenix.com/

Copyright

1 Year (MM) Chart

1 Year (MM) Chart

1 Month (MM) Chart

1 Month (MM) Chart